A partir de tradutores profissionais, empresas, páginas da web e repositórios de traduções disponíveis gratuitamente
nederland valeant pharmaceuticals benelux & scandinavia b. v.
nederland valeant pharmaceuticals benelux & scandinavia b. v.
deutschland valeant pharmaceuticals germany gmbh tel: +49 (0) 6196 99 88 90
deutschland valeant pharmaceuticals germany gmbh tel: +49 (0) 6196 99 88 90
latvija valeant pharmaceuticals switzerland gmbh representative office in latvia tel: +371 7 616 137
latvija valeant pharmaceuticals switzerland gmbh representative office in latvia tel: +371 7 616 137
valeant canada limited commits itself to produce a new lot of carbolith 150 mg capsules as soon as possible.
valeant canada limitée s’engage à produire un nouveau lot de capsules de carbolith 150 mg aussitôt que possible.
vae valeant canada limited vao valeo pharma incorporated vir virco pharmaceuticals canada incorporated vlb vitalab vth vita health products incorporated
vae valeant canada limitée vao valeo pharma incorporé vir virco pharmaceuticals canada incorporé vlb vitalab vth vita health products incorporé
52(se danmark)Österreich valeant pharmaceuticals austria gmbh tel: +43 (0) 463 590 832
malta vivian cooporation tel: +356-21344610nederland valeant pharmaceuticals benelux scandinavia b. v.tel: +31 (0) 79 330 2424norge (se danmark)Österreich valeant pharmaceuticals austria gmbh tel: +43 (0) 463 590 832
slovenská republika valeant czech pharma s. r. o. – oz tel: +421 (0) 6920 3921
slovenská republika valeant czech pharma s. r. o. – oz tel: +421 (0) 6920 3921
as a precaution, valeant canada limited recommends physicians to re-evaluate patients on carbolith 150 mg by monitoring serum lithium levels and exercising clinical and laboratory surveillance over possible side effects.
par mesure de précaution, valeant canada limitée recommande aux médecins de réévaluer par le moyen d’analyses sanguines les patients qui consomment des capsules de carbolith 150 mg et de pratiquer une surveillance clinique et chimique des effets secondaires qui pourraient survenir.
eli lilly originally received approval from the american medicines control agency fda (food and drug administration) for nabilone in 1985 but withdrew it from the market in 1989, valeant said.
valeant a déclaré que eli lilly avait obtenu l’autorisation de mise sur le marché pour la nabilone en 1985 par la fda (food and drug administration) et qui, en 1989, l’avait à nouveau retirée.